Table 4.
IMGT engineered variant nomenclature. Examples of IGHG1 variants involved in antibody-dependent cellular (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), half-life increase, half-IG exchange, B cell inhibition, and knobs-into-holes are shown. Amino acid positions, correspondence with the EU numbering and bibliographical references are quoted at http://www.imgt.org/IMGTeducation/Tutorials/IGandBcells/_UK/IGproperties/Tableau3.html.
| IMGT Engineered Variant Nomenclature | IGHG Gene Variant Description | Property Modifications | |||||
|---|---|---|---|---|---|---|---|
| CH2 | AA and IMGT Position in CH2 of IGHG Gene Variant | CH3 | AA and IMGT Position in CH3 of IGHG Gene Variant | ADCC Enhancement or Reduction, ADCP Enhancement, B Cell Inhibition | CDC Enhancement or Reduction | Half-IG Exchange Reduction, Half-Life Increase, Knobs-Into-Holes | |
| Homsap IGHG1v1 | CH2 | P1.4 | ADCC reduction | ||||
| Homsap IGHG1v2 | CH2 | V1.3 | ADCC reduction | ||||
| Homsap IGHG1v3 | CH2 | A1.2 | ADCC reduction | ||||
| Homsap IGHG1v4 | CH2 | A114 | ADCC reduction | CDC reduction | |||
| Homsap IGHG1v5 | CH2 | W109 | ADCC reduction | CDC enhancement | |||
| Homsap IGHG1v6 | CH2 | A85.4, A118, A119 | ADCC enhancement | ||||
| Homsap IGHG1v7 | CH2 | D3, E117 | ADCC enhancement | ||||
| Homsap IGHG1v8 | CH2 | D3, L115, E117 | ADCC enhancement | CDC reduction | |||
| Homsap IGHG1v9 | CH2 | L7, P83, L85.2, I88 | CH3 | L83 | ADCC enhancement | ||
| Homsap IGHG1v10 | CH2 | Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 | ADCC enhancement | ||||
| Homsap IGHG1v11 | CH2 | E34, D109, M115, E119 | ADCC enhancement | ||||
| Homsap IGHG1v12 | CH2 | A1.1, D3, L115, E117 | ADCC enhancement | ||||
| Homsap IGHG1v13 | CH2 | A1.1, D3, E117 | ADCP enhancement | ||||
| Homsap IGHG1v14 | CH2 | A1.3, A1.2 | ADCC reduction | CDC reduction | |||
| Homsap IGHG1v15 | CH2 | S118 | CDC enhancement | ||||
| Homsap IGHG1v16 | CH2 | W109, S118 | CDC enhancement | ||||
| Homsap IGHG1v17 | CH2 | E29, F30, T107 | CDC enhancement | ||||
| Homsap IGHG1v18 | CH3 | R1, G109, Y120 | CDC enhancement | ||||
| Homsap IGHG1v19 | CH2 | A34 | CDC reduction | ||||
| Homsap IGHG1v20 | CH2 | A105 | CDC reduction | ||||
| Homsap IGHG1v21 | CH2 | Y15.1, T16, E18 | Half-life increase | ||||
| Homsap IGHG1v22 | CH2 | Y15.1, T16, E18 | CH3 | K113, F114, H116 | Half-life increase | ||
| Homsap IGHG1v23 | CH2 | E1.2 | ADCC reduction | CDC reduction | |||
| Homsap IGHG1v24 | CH3 | L107, S114 | Half-life increase | ||||
| Homsap IGHG1v25 | CH2 | E29, F113 | B cell inhibition | ||||
| Homsap IGHG1v26 | CH3 | Y22, T86 | Knobs-into-holes | ||||